Rad/Nuc News: First-In-Human Trial of Oral Drug to Remove Radioactive Contamination Begins

Trial is testing escalating doses of the investigational drug product HOPO 14-1 in healthy adults.

Monday, May 15, 2023 First-In-Human Trial of Oral Drug to Remove Radioactive Contamination Begins International ionizing radiation warning symbol A first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body has begun. The trial is testing the safety, tolerability and processing in the body of escalating doses of the investigational drug product HOPO 14-1 in healthy adults. NIAID is funding the Phase 1 trial, which is sponsored and conducted by SRI International of Menlo Park, California. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107